The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Hypoxia-inducible factor-2a (HIF-2a) inhibitor belzutifan in von Hippel-Lindau (VHL) disease–associated neoplasms: 5-year follow-up of the phase 2 LITESPARK-004 study.
 
Vivek Narayan
Honoraria - Pfizer
Consulting or Advisory Role - AstraZeneca; Eisai; Exelixis; Janssen Oncology; Merck; Myovant Sciences; Pfizer/Astellas; Regeneron; Sanofi; Terns Pharmaceuticals; Xencor
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Merck (Inst); Pfizer (Inst); Regeneron (Inst); Xencor (Inst)
Patents, Royalties, Other Intellectual Property - US Patent No. 18/708,529
Travel, Accommodations, Expenses - Eisai; Exelixis; Pfizer
 
Eric Jonasch
Consulting or Advisory Role - Aveo; Eisai; Exelixis; GlaxoSmithKline; Ipsen; Merck; NiKang Therapeutics; Novartis; Takeda; Telix Pharmaceuticals
Research Funding - Abbvie (Inst); Arrowhead Pharmaceuticals (Inst); Aveo (Inst); Corvus Pharmaceuticals (Inst); Merck (Inst); NiKang Therapeutics (Inst); ProfoundBio (Inst); Telix Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Othon Iliopoulos
Employment - Chiesi (I)
Consulting or Advisory Role - Merck
 
Benjamin Maughan
Consulting or Advisory Role - Astellas Medivation; AVEO; Bavarian Nordic; Bayer; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Janssen Oncology; Lilly; Merck; Peloton Therapeutics; Pfizer; Sanofi; Telix Pharmaceuticals; Tempus; Xencor
Research Funding - Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Exelixis (Inst)
Travel, Accommodations, Expenses - Exelixis
 
Stephane Oudard
Honoraria - BMS, Bayer, Ipsen, Eisai, MSD, Janssen, Astellas, Amgen, Sanofi
Consulting or Advisory Role - BMS, Bayer, Ipsen, Eisai, MSD, Janssen, Astellas, Amgen, Sanofi
Research Funding - BMS, Bayer, Ipsen, Eisai, MSD, Janssen, Astellas, Amgen, Sanofi
Travel, Accommodations, Expenses - Ipsen, Janssen, Roche, Sanofi, Bayer
 
Tobias Else
Consulting or Advisory Role - Merck
 
Jodi Maranchie
Research Funding - Janssen (Inst); Merck (Inst)
Other Relationship - Elsevier
 
Ane Bundsbæk Bøndergaard Iversen
No Relationships to Disclose
 
Katy Beckermann
Consulting or Advisory Role - Adicet Bio; Alpine Immune Sciences; Aravive; Arcus Biosciences; AstraZeneca; AVEO; Bristol-Myers Squibb; Eisai; Exelixis; Merck; Nimbus Therapeutics; Xencor
Research Funding - Aravive (Inst); ArsenalBio (Inst); Bristol-Myers Squibb; Pionyr (Inst)
 
Jerry Cornell
Employment - Merck
 
Rodolfo Perini
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Yanfang Liu
Employment - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck
 
W Linehan
No Relationships to Disclose
 
Ramaprasad Srinivasan
Research Funding - a. Peloton/Merck and Nikang: Funds paid to the Institution via a CRADA to partially defray the costs of clinical studies b. My relationships with all the listed entities includes: serving as site or overall PI of studies and/or on study steering committee (Inst); Peloton/ Merck*, Genentech, Novartis, Nikang Therapeutics* (see comments) (Inst)